- Home
- JYNT vs ELDN Comparison
JYNT vs ELDN Comparison
Compare JYNT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- ELDN
- Stock Information
- Founded
- JYNT 2010
- ELDN 2004
- Country
- JYNT United States
- ELDN United States
- Employees
- JYNT N/A
- ELDN N/A
- Industry
- JYNT Multi-Sector Companies
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- ELDN Health Care
- Exchange
- JYNT Nasdaq
- ELDN Nasdaq
- Market Cap
- JYNT 170.1M
- ELDN 178.4M
- IPO Year
- JYNT 2014
- ELDN N/A
- Fundamental
- Price
- JYNT $9.99
- ELDN $2.89
- Analyst Decision
- JYNT Strong Buy
- ELDN Strong Buy
- Analyst Count
- JYNT 2
- ELDN 1
- Target Price
- JYNT $15.50
- ELDN $16.00
- AVG Volume (30 Days)
- JYNT 62.5K
- ELDN 160.2K
- Earning Date
- JYNT 05-08-2025
- ELDN 05-20-2025
- Dividend Yield
- JYNT N/A
- ELDN N/A
- EPS Growth
- JYNT N/A
- ELDN N/A
- EPS
- JYNT N/A
- ELDN N/A
- Revenue
- JYNT $52,789,479.00
- ELDN N/A
- Revenue This Year
- JYNT $10.88
- ELDN N/A
- Revenue Next Year
- JYNT $12.11
- ELDN N/A
- P/E Ratio
- JYNT N/A
- ELDN N/A
- Revenue Growth
- JYNT N/A
- ELDN N/A
- 52 Week Low
- JYNT $9.58
- ELDN $2.00
- 52 Week High
- JYNT $17.82
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- JYNT 44.27
- ELDN 40.93
- Support Level
- JYNT $9.61
- ELDN $2.85
- Resistance Level
- JYNT $10.60
- ELDN $3.51
- Average True Range (ATR)
- JYNT 0.52
- ELDN 0.27
- MACD
- JYNT 0.06
- ELDN -0.01
- Stochastic Oscillator
- JYNT 29.23
- ELDN 5.63
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.